Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

138.18 +0.54 (+0.39%)
Official Closing Price Updated: 7:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
This Foreboding Sign Looms Over AbbVie's Chart
 
Via Benzinga
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
$300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement
These three stocks have all produced market-beating returns for shareholders in recent years. 
Via The Motley Fool
AbbVie Unusual Options Activity
 
Via Benzinga
Why Is AbbVie Stock Trading Down Today?
AbbVie Inc. (NYSE: ABBV) shares are trading lower Thursday after Coherus BioSciences Inc. 
Via Benzinga
Why AbbVie and Amgen Are Moving Lower Today
An ultra-low-priced biosimilar may negatively impact both biotechs. 
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
7 Best Dividend Stocks to Buy Now in June 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug... 
Via Benzinga
AbbVie Unusual Options Activity
 
Via Benzinga
2 Top Dividend Kings to Buy for the Long Haul
Dividend stocks are an easy way to earn passive income. 
Via The Motley Fool
AbbVie Unusual Options Activity
 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,200 Today
 
Via Benzinga
AbbVie Unusual Options Activity
 
Via Benzinga
2 Dividend Kings on Sale That Are Yielding More Than 4%
Before you rush out to buy these stocks, you should consider the risks that come with them. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Clinical Triumph: MEI Pharma's Voruciclib Demonstrates Encouraging Activity in AML Patients
MEI Pharma Inc (NASDAQ: MEIP) announced an update to the Phase 1 study of voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, in patients with relapsed and refractory (R/R) acute... 
Via Benzinga
Why Ironwood Pharmaceuticals Stock Bumped Higher Today
Investors indicated approval of the company's upcoming $1 billion asset purchase. 
Via The Motley Fool
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Both companies are working on treatments for gastrointestinal diseases. 
Via Investor's Business Daily
What Does AbbVie's Debt Look Like?
 
Via Benzinga
This Is What Whales Are Betting On AbbVie
 
Via Benzinga
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
If the economy falters, these stocks should hold up better than most. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now
The decisions are easy with these dividend stocks. 
Via The Motley Fool
FDA Approves AbbVie/Genmab's Cancer Drug As First Bispecific Antibody For Type Of Lymphoma In Adult Patients
The FDA has approved Epkinly (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)... 
Via Benzinga
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to  
Via Benzinga
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
Benzinga 
Via Benzinga
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
41 42 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.